AVII h5n1 AVII h5n1 AVII AVII h5n1 AVII AVII AVII - 500 Beiträge pro Seite

[opelmanta3]

AVI BioPharma Reports Confirmation of Efficacy against Influenza Strains
Friday January 20, 9:00 am ET
NEUGENE Antisense Efficacy against Influenza Strains, Including Avian Influenza, to Lead to IND Filing with the FDA


PORTLAND, Ore.--(BUSINESS WIRE)--Jan. 20, 2006--AVI BioPharma, Inc. (Nasdaq:AVII - News) today announced confirmation from three independent laboratories of NEUGENE® antisense efficacy in preclinical experiments against multiple strains of influenza, including avian influenza strain H5N1.
Dr. P. Puthavathana at Mahidol University in Bangkok, Thailand, confirmed NEUGENE antisense efficacy against an H5N1 viral isolate in her assay system.
Dr. Darwyn Kobasa at the Public Health Agency of Canada in Winnipeg, Manitoba, completed an initial dose-response study in cell culture demonstrating NEUGENE efficacy against both the H1N1 and H3N2 strains.
Dr. Manoj Pastey at Oregon State University in Corvallis, Ore., confirmed efficacy using the same NEUGENE antisense agents against the H7N7 and H3N8 strains.
Taken together, these data confirm efficacy observed with the H1N1 strain previously reported from Drs. Jianzhu and Chen Qin Ge at Massachusetts Institute of Technology in Boston and now represent positive reports from four laboratories using different endpoints and methodologies.

"These confirmations validate our approach to blocking replication of influenza viruses. We now believe that a single NEUGENE drug could be effective against most influenza subtypes, including the H5N1 avian strain," said Patrick L. Iversen, Ph.D., senior vice president of research and development at AVI. "By targeting regions of the viral genetic code that are common to all influenza A subtypes, we expect that our NEUGENE drugs will be effective against avian flu and the far more common influenza A viruses, which kill an average of 35,000 Americans every year."

AVI is also conducting collaborative animal studies evaluating NEUGENE efficacy against influenza strains at Tulane University in New Orleans and at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID) in Frederick, Maryland.

"Based on these recent findings and other results from additional studies, AVI now plans to file an Investigative New Drug (IND) application with the FDA for the treatment of influenza A virus with NEUGENE antisense drugs," said Denis R Burger, Ph.D., chief executive officer of AVI. "We feel confident in the safety, efficacy and potency of our NEUGENE drugs targeting influenza and plan to move forward into the clinical trial process later this year."

AVI`s NEUGENE antisense drug development program against the influenza A virus specifically targets genetic regions of the virus that are highly conserved between six viral subtypes that cause human disease. These include three subtypes that caused pandemics in the 20th century -- the 1918 Spanish flu (H1N1), the 1957 Asian flu (H2N2) and the 1968 Hong Kong flu (H3N2) -- and three subtypes of avian flu that have been reported to cause disease in humans (H5N1, H7N7 and H9N2).

[opelmanta3]

beim durchbrechen von 7.48

wird der wiederstand unsere unterstützung

20 $ wir kommen

[opelmanta3]

$ 8

[link68]

Auch schon infiziert oder woher der Threadtitel?

[opelmanta3]

bei EMFP sehe ich ähnliches potential...

ihre nanomaske und filter gegen H5N1

wenn die ne gute nachricht posten über testresultate oder die quartalszahlen (die absätze quasi von 0 auf milionen)

sehe ich hier schnell die 2.50


momentan EMFP .70

[opelmanta3]

8.88 im höchst...das lob ich mir...

montag nochmal verdoppeln dann ist mein kursziel schon fast erreicht